# Efficacy of Allogeneic UCMSCs for Treating Large Defects Knee Injury

> **NCT05016011** · PHASE2 · COMPLETED · sponsor: **Cytopeutics Sdn. Bhd.** · enrollment: 28 (actual)

## Conditions studied

- Osteoarthritis, Knee

## Interventions

- **BIOLOGICAL:** Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
- **PROCEDURE:** Marrow cellution

## Key facts

- **NCT ID:** NCT05016011
- **Lead sponsor:** Cytopeutics Sdn. Bhd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-01
- **Primary completion:** 2022-03-21
- **Final completion:** 2022-03-21
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05016011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05016011, "Efficacy of Allogeneic UCMSCs for Treating Large Defects Knee Injury". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05016011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*